Recurrent Adult Immunoblastic Large Cell Lymphoma Completed Phase 2 Trials for DB01609 (Deferasirox)

IndicationStatusPhase
DBCOND0028500 (Recurrent Adult Immunoblastic Large Cell Lymphoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01273766Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic MalignanciesSupportive Care